Tempest Therapeutics stock surges after H.C. Wainwright upgrade By Investing.com
Tempest Therapeutics stock surges after H.C. Wainwright upgrade…
2,360$
2,16%
Echtzeit-Aktienkurs TEMPEST THERAP. DL-,01
Bid:
Ask:
Nachrichten zur TEMPEST THERAP. DL-,01 Aktie
Tempest Therapeutics receives Nasdaq notice for annual meeting compliance By Investing.com
Tempest Therapeutics receives Nasdaq notice for annual meeting compliance…
Tempest Therapeutics closes $4.25 million registered direct offering By Investing.com
Tempest Therapeutics closes $4.25 million registered direct offering…
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
BRISBANE, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- In a transaction designed to both expand its pipeline and…
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
BRISBANE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…
Tempest Therapeutics files for mixed shelf offering of up to $300M
…
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…
Tempest Reports Year End 2023 Financial Results and Provides Business Update
BRISBANE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing…